ROQ Share Price Performance
Recent ROQ News & Updates
No updates
Roquefort Therapeutics plc Key Details
Last Reported Earnings
Dec 31, 2024
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.0062
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 8.2%
Roquefort Therapeutics plc Competitors
About ROQ
- Founded
- 2020
- Employees
- 7
- CEO
- WebsiteView website
Roquefort Therapeutics plc, a material biotech company, engages in the development of medicines for the treatment of cancer. Its product portfolio consists of five novel patent-protected pre-clinical anti-cancer medicines, which include Midkine antibodies with significance in vivo efficacy and toxicology studies, as well as orphan drug indication; Midkine RNA oligonucleotide therapeutics with novel anti-cancer gene editing action; Midkine mRNA therapeutics for solid tumors; STAT-6 siRNA therapeutics targeting solid tumors with significance in vivo efficacy; and MK cell therapy with direct and natural killer cell-mediated anti-cancer action. The company was incorporated in 2020 and is based in London, the United Kingdom.
U.K. Market Performance
- 7 Days: 1.6%
- 3 Months: 7.6%
- 1 Year: 7.9%
- Year to Date: 8.1%
Over the last 7 days, the market has risen 1.1%, driven by gains of 5.3% in the Materials sector. As for the past 12 months, the market is up 7.4%. Earnings are forecast to grow by 15% annually. Market details ›
The tide is turning for UK & European markets. Index ETFs won’t cut it since sector spreads are massive. Picking the right companies matters now more than ever.
Continue readingLast Week
